Display options
Cite
Sawicki A, Szulc P, Sobczyk T, et al. Influence of calcitonin treatment on the osteocalcin concentration in the algodystrophy of bone. Clin Rheumatol. 1992;11(3):346-50doi: 10.1007/BF02207191.
Sawicki, A., Szulc, P., Sobczyk, T., Goliszewski, J., Garnier, P., & Labuszewski, R. (1992). Influence of calcitonin treatment on the osteocalcin concentration in the algodystrophy of bone. Clinical rheumatology, 11(3), 346-50. https://doi.org/10.1007/BF02207191
Sawicki, A, et al. "Influence of calcitonin treatment on the osteocalcin concentration in the algodystrophy of bone." Clinical rheumatology vol. 11,3 (1992): 346-50. doi: https://doi.org/10.1007/BF02207191
Sawicki A, Szulc P, Sobczyk T, Goliszewski J, Garnier P, Labuszewski R. Influence of calcitonin treatment on the osteocalcin concentration in the algodystrophy of bone. Clin Rheumatol. 1992 Sep;11(3):346-50. doi: 10.1007/BF02207191. PMID: 1281061.
Copy Download .nbib Format: NLM
Share it on

Clin Rheumatol. 1992 Sep;11(3):346-50. doi: 10.1007/BF02207191.

Influence of calcitonin treatment on the osteocalcin concentration in the algodystrophy of bone.

Clinical rheumatology

A Sawicki, P Szulc, T Sobczyk, J Goliszewski, P Garnier, R Labuszewski

Affiliations

  1. Dept. Neuroendocrinology, Medical Center for Postgraduate Education, Warsaw, Poland.

PMID: 1281061 DOI: 10.1007/BF02207191

Abstract

Algodystrophy (AD) attacks all tissues in the affected region and results in the rapid demineralization of bones. Osteocalcin (OC) and alkaline phosphatase (AP) are markers of bone turnover. Calcitonin is the treatment of choice of AD. Two groups of patients were studied: Group I (n = 8)--acute stage of AD (before and during the calcitonin treatment), Group II (n = 5)--late chronic stage of AD. In the acute stage of AD both OC level and AP activity were increased. They were normal in the chronic stage of AD. During the calcitonin treatment OC level normalized after 14 days and then increased again. During the treatment, AP activity temporarily increased and then returned to the initial level. We confirm that an increased bone turnover is observed in the acute stage of AD. Discrepancy between OC level and AP activity reflects the local metabolic disturbances. Salmon calcitonin inhibits the algodystrophic process and probably contributes to the activation of the skeletal restoration.

References

  1. Rev Rhum Mal Osteoartic. 1981 Apr;48(4):315-21 - PubMed
  2. J Clin Endocrinol Metab. 1987 Jul;65(1):89-94 - PubMed
  3. J Orthop Res. 1986;4(2):180-7 - PubMed
  4. J Clin Invest. 1988 Sep;82(3):861-5 - PubMed
  5. Med Welt. 1981 Sep 11;32(37):1375-7 - PubMed
  6. J Pharm Pharmacol. 1980 Mar;32(3):192-5 - PubMed
  7. Ann Chir Main. 1986;5(2):93-104 - PubMed
  8. Rev Rhum Mal Osteoartic. 1982 Dec;49(12 ):883-5 - PubMed
  9. Rev Rhum Mal Osteoartic. 1978 Dec;45(12):691-8 - PubMed
  10. Rev Rhum Mal Osteoartic. 1982 Dec;49(12):879-82 - PubMed
  11. J Bone Miner Res. 1986 Dec;1(6):539-42 - PubMed
  12. Rev Med Liege. 1986 Dec 15;41(24):996-1003 - PubMed
  13. Clin Rheumatol. 1988 Jun;7(2):173-80 - PubMed
  14. J Bone Miner Res. 1986 Dec;1(6):563-71 - PubMed
  15. Rev Rhum Mal Osteoartic. 1982 Dec;49(12 ):887-90 - PubMed
  16. Life Sci. 1979 Nov 19;25(21):1851-5 - PubMed
  17. J Nucl Med Allied Sci. 1982 Jul-Sep;26(3):173-9 - PubMed
  18. J Radiol. 1988 Aug-Sep;69(8-9):495-500 - PubMed
  19. Ann Intern Med. 1972 May;76(5):833 - PubMed
  20. J Foot Surg. 1986 Mar-Apr;25(2):149-53 - PubMed
  21. Rev Rhum Mal Osteoartic. 1983 Jan;50(1):23-31 - PubMed
  22. Rev Rhum Mal Osteoartic. 1979 Apr;46(4):235-41 - PubMed
  23. J Biol Chem. 1984 Mar 25;259(6):3511-8 - PubMed
  24. Calcif Tissue Int. 1988 Jan;42(1):13-7 - PubMed
  25. Ann Anat Pathol (Paris). 1958 Oct-Dec;3(4):477-511 - PubMed
  26. Oncology. 1986;43(5):283-7 - PubMed
  27. Calcif Tissue Int. 1986 Jun;38(6):328-32 - PubMed
  28. Calcif Tissue Int. 1989 Oct;45(4):214-21 - PubMed
  29. Clin Chem. 1987 Dec;33(12):2171-7 - PubMed
  30. Nature. 1961 Apr 29;190:460-1 - PubMed
  31. Z Orthop Ihre Grenzgeb. 1989 Mar-Apr;127(2):202-6 - PubMed
  32. J Clin Endocrinol Metab. 1986 Nov;63(5):1080-5 - PubMed
  33. Clin Orthop Relat Res. 1987 Feb;(215):217-22 - PubMed
  34. Fortschr Med. 1981 May 21;99(19):712-20 - PubMed
  35. Rev Rhum Mal Osteoartic. 1987 Oct;54(10 ):655-9 - PubMed

Substances

MeSH terms

Publication Types